Skip to content

Company
Pipeline
For Investors
Contact

Company
Pipeline
For Investors
Contact

Press Releases

Choose Year
Search Press Releases

Found 270 Results

April 4, 2022

Relmada Therapeutics to Present Data at the Ketamine & Related Compounds International Hybrid Conference 2022

March 23, 2022

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

March 16, 2022

Relmada Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 23, 2022

March 10, 2022

Relmada Therapeutics to Participate in Fireside Chats at Two Upcoming Healthcare Events

February 23, 2022

Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential

February 10, 2022

Relmada Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

December 22, 2021

Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry

December 14, 2021

Relmada Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

December 8, 2021

Relmada Therapeutics Announces Proposed Public Offering of Common Stock

December 8, 2021

Relmada Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

«...8 91011 12 13...»

IR Contact

Brian Ritchie
LifeSci Advisors, LLC

+1 (212) 915-2578
britchie@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Company

Pipeline
Overview
NDV-01
Speranolone

For Investors
Summary
News
Events
SEC Filings
Corporate Governance
Stock Information

Contact

info@relmada.com

+1 (786) 629-1376

©2026 Relmada Therapeutics, Inc.

Privacy Policy
Terms of Use

Scroll to Top